| abstract |
Reversible and irreversible inhibitors of brutonyl tyrosine kinase (Btk) are disclosed herein. Pharmaceutical compositions comprising such compounds are also disclosed. The method of using the Btk inhibitor is described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, xenogeneic immune diseases or conditions, cancers including lymphomas, and inflammatory diseases or conditions. |